Skip to main content

Field Safety Corrective Actions

Overview​

A Field Safety Corrective Action (FSCA) is a corrective action taken by a manufacturer or sponsor to reduce a risk of death or serious deterioration in the health of a patient or user associated with a medical device that has already been placed on the market. Under the PRAC, FSCAs are captured within the umbrella of "market actions" — they may be classified as a Recall, Product Alert, Product Correction, or Quarantine depending on the nature of the action required.

The term FSCA remains in common use internationally (especially in the EU/MDR context) and sponsors and manufacturers familiar with EU terminology will find the Australian PRAC requirements broadly equivalent.

Types of FSCAs Under PRAC​

Product Correction (most common FSCA type) Where the device can remain in use but a correction is needed — for example:

  • A software update to address a safety-related defect
  • A labelling update or additional warning to accompany the device
  • Modified instructions for use issued to all healthcare facilities using the device
  • A modification to the device's cleaning or reprocessing instructions

Recall Where the device must be removed from use or from the market — for example:

  • Devices with a manufacturing defect that cannot be corrected in the field
  • Devices where continued use poses an unacceptable risk even with additional warnings

Product Alert Where users need to be notified of a potential issue, but the device can continue to be used with appropriate precautions, without requiring product return or correction.

Field Safety Notices (FSNs)​

A Field Safety Notice (FSN) is the written communication sent to affected customers (healthcare facilities, users, distributors) to inform them of the FSCA and the action they must take. Under PRAC, the TGA must approve the sponsor's recall strategy and customer communication (the FSN) before it is issued — except where an imminent safety threat requires immediate action.

An effective FSN includes:

  • Clear identification of the affected devices (model, lot/batch numbers, serial numbers, UDI)
  • Description of the safety issue
  • Assessment of the risk to patients
  • Actions required of the recipient (return, quarantine, modification, enhanced monitoring)
  • Contact details for the sponsor
  • Timeline for required actions
  • Instructions for acknowledging receipt

Overseas FSCAs Affecting Australian-Supplied Devices​

If an overseas manufacturer initiates an FSCA in another country for devices that have been supplied in Australia, the Australian sponsor must:

  1. Notify the TGA Recalls team as soon as they become aware of the overseas action
  2. Assess whether Australian-supplied devices are affected (same batch, same manufacturing period, same component)
  3. Initiate an equivalent Australian market action if Australian devices are affected
  4. Not assume that an overseas FSCA automatically applies to Australian devices — nor assume it doesn't

The TGA closely monitors overseas regulatory databases (FDA MAUDE, EU EUDAMED, MHRA) and may contact sponsors about overseas FSCAs before the sponsor has been notified by their manufacturer.

PRAC Process Summary​

The PRAC reduces the recall process to five key steps:

  1. Notify the TGA — immediately upon identifying a potential market action trigger
  2. Submit a recall strategy — including proposed market action type, class, distribution reach, FSN draft
  3. TGA reviews and approves the strategy (or requests modifications)
  4. Execute the market action — issue FSN, implement corrective actions, track responses
  5. Submit a close-out report to the TGA confirming the action is complete

Official Sources​